A novel protocol for postpartum magnesium sulphate in severe pre-eclampsia: a randomized controlled pilot trial

Area of Science:

• Obstetrics and Gynecology
• Pharmacology
• Critical Care Medicine

Background:

• Severe pre-eclampsia poses a significant risk of seizures (eclampsia).
• Magnesium sulphate is the standard anticonvulsant prophylaxis.
• Optimal postpartum dosing regimens require further investigation.

Purpose of the Study:

• To compare the effectiveness of three postpartum magnesium sulphate protocols in preventing eclampsia.
• To evaluate seizure prevention in severe pre-eclampsia using single-dose, 12-hour abbreviated, and 24-hour standard protocols.

Main Methods:

• A double-blind, randomized controlled pilot trial involving 240 women with severe pre-eclampsia.
• Participants received intravenous magnesium sulphate postpartum, allocated to: single loading dose (Group I), 12-hour protocol (Group II), or 24-hour protocol (Group III).
• Outcomes included eclampsia incidence, liver enzymes, platelet counts, ICU admission, and flushing.

Main Results:

• No significant differences were observed in eclampsia incidence, liver enzymes, low platelets, or ICU admissions among the groups.
• Flushing occurred significantly more often in the 24-hour standard protocol group (30%) compared to the 12-hour (15%) and single-dose (5%) groups.

Conclusions:

• The single-loading dose postpartum regimen is a potential alternative for preventing eclampsia in severe pre-eclampsia.
• Further large-scale clinical trials are warranted to confirm these findings.
• The single-dose regimen may offer a favorable side-effect profile compared to longer protocols.